TITLE:
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

CONDITION:
Postmenopausal Osteoporosis

INTERVENTION:
MK0217, alendronate sodium/Duration of Treatment: 6 months

SUMMARY:

      This study is to assess the safety and tolerability of MK0217 being evaluated to treat women
      with postmenopausal osteoporosis.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 25 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Women with postmenopausal osteoporosis

        Exclusion Criteria:

          -  High risk for fractures

          -  Esophageal abnormalities

          -  Upper gastrointestinal symptoms that are not relieved with medication

          -  Metabolic bone disease (example - vitamin D deficiency)

          -  Medications that would affect the breakdown or build-up of bone
      
